Q3 EPS Forecast for Adherex Technologies Reduced by Analyst

Adherex Technologies Inc. (NASDAQ:FENC) – Analysts at HC Wainwright decreased their Q3 2025 EPS estimates for Adherex Technologies in a research note issued on Thursday, August 21st. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.09) per share for the quarter, down from their previous estimate of ($0.04). HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Adherex Technologies’ current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Adherex Technologies’ FY2025 earnings at ($0.25) EPS and FY2026 earnings at $0.65 EPS.

Several other equities analysts also recently weighed in on FENC. Wall Street Zen raised shares of Adherex Technologies from a “hold” rating to a “buy” rating in a report on Sunday, August 17th. Craig Hallum lifted their price target on shares of Adherex Technologies from $13.00 to $14.00 and gave the company a “buy” rating in a report on Friday, August 15th. Finally, Zacks Research downgraded shares of Adherex Technologies from a “strong-buy” rating to a “hold” rating in a report on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $13.33.

Adherex Technologies Price Performance

Shares of NASDAQ:FENC opened at $8.68 on Monday. Adherex Technologies has a 1-year low of $3.96 and a 1-year high of $9.42. The company has a market capitalization of $241.39 million, a P/E ratio of -20.67 and a beta of 0.40. The firm’s 50 day simple moving average is $8.45 and its two-hundred day simple moving average is $7.23.

Adherex Technologies (NASDAQ:FENC) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.05). The business had revenue of $9.76 million for the quarter, compared to analyst estimates of $9.52 million.

Insider Buying and Selling at Adherex Technologies

In related news, Director Rosty Raykov sold 10,000 shares of the company’s stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $8.09, for a total transaction of $80,900.00. Following the completion of the transaction, the director owned 55,878 shares in the company, valued at approximately $452,053.02. This represents a 15.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 31,119 shares of company stock worth $254,546 in the last three months. 10.98% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Adherex Technologies

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE raised its stake in Adherex Technologies by 32.1% during the fourth quarter. Bank of America Corp DE now owns 35,827 shares of the company’s stock valued at $226,000 after purchasing an additional 8,703 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Adherex Technologies by 11.5% during the fourth quarter. BNP Paribas Financial Markets now owns 44,626 shares of the company’s stock valued at $282,000 after purchasing an additional 4,610 shares in the last quarter. Barclays PLC raised its stake in Adherex Technologies by 13.9% during the fourth quarter. Barclays PLC now owns 35,672 shares of the company’s stock valued at $225,000 after purchasing an additional 4,353 shares in the last quarter. Wells Fargo & Company MN raised its stake in Adherex Technologies by 31.6% during the fourth quarter. Wells Fargo & Company MN now owns 13,152 shares of the company’s stock valued at $83,000 after purchasing an additional 3,155 shares in the last quarter. Finally, MetLife Investment Management LLC purchased a new stake in Adherex Technologies during the fourth quarter valued at $99,000. Institutional investors own 55.51% of the company’s stock.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.